Hydrocortisone / neomycin / polymyxin b ophthalmic Disease Interactions
There are 2 disease interactions with hydrocortisone / neomycin / polymyxin b ophthalmic:
Ophthalmic Corticosteroids (Includes Hydrocortisone/neomycin/polymyxin b ophthalmic) ↔ Ocular Infections
Severe Potential Hazard, High plausibility
Applies to: Ocular Infection
The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation. In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents. Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy. If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.
- "Product Information. FML Ophthalmic Suspension (fluoromethalone ophthalmic)." Allergan Inc, Irvine, CA.
- "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Co, Inc, West Point, PA.
- "Product Information. Pred Forte (prednisolone ophthalmic)." Allergan Inc, Irvine, CA.
Ophthalmic Corticosteroids (Includes Hydrocortisone/neomycin/polymyxin b ophthalmic) ↔ Ocular Toxicities
Severe Potential Hazard, High plausibility
Applies to: Cataracts, Glaucoma/Intraocular Hypertension
Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure. If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children. The equatorial and posterior subcapsular portions of the lens should be examined for changes.
- Francois J "Corticosteroid glaucoma." Ann Ophthalmol 9 (1977): 1075-80
- Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42
- Foster CS, Alter G, Debarge LR, Raizman MB, Crabb JL, Santos CI, Feiler LS, Friedlaender MH "Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis." Am J Ophthalmol 122 (1996): 171-82
hydrocortisone / neomycin / polymyxin b ophthalmic drug Interactions
There are 8 drug interactions with hydrocortisone / neomycin / polymyxin b ophthalmic
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
|Major||Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderate||Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minor||Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.